文献速递造血干细胞移植与细胞治疗

血液与骨髓移植临床试验网络1702主要结果:替代供者异基因移植的临床移植相关长期结局

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.
PubMed 文献 · J Clin Oncol · 2025-09-18

这项多中心生物学分配试验纳入1751例可评估患者,按找到相合无关供者可能性分为极可能(54.7%)、较少可能(29.5%)和极不可能(15.8%)三组。极不可能组与极可能组2年生存率无统计学差异(多因素HR 1.07,95%CI 0.86-1.33,P=0.56),移植后复发、治疗相关死亡、无病生存及急慢性移植物抗宿主病在三组间亦无差异。

要点

  • 极不可能找到相合无关供者者使用替代供者移植,2年生存与极可能找到者无统计学差异。
  • 移植患者中相合无关供者使用率:极可能组94%、较少可能组38%、极不可能组9%。
  • 三组移植后复发、治疗相关死亡、无病生存及急慢性GVHD均无差异。

核心结论

  • 使用供者搜索预后评分策略优先为极不可能找到相合无关供者的患者选择替代供者,其生存和移植结局与极可能找到相合无关供者的患者相比无统计学差异。

研究设计与样本

  • 由血液与骨髓移植临床试验网络开展的多中心生物学分配试验(BMT CTN 1702),纳入标准宽泛以反映临床实践。
  • 共1751例可评估患者,来自47个中心;主要终点为自可评估起2年生存,比较极可能(>90%)与极不可能(<10%)找到相合无关供者两组。
  • 较少可能找到相合无关供者的其他患者进入观察组,比较三组移植结局。

主要发现

  • 可评估患者中极可能、较少可能、极不可能找到相合无关供者者分别占54.7%、29.5%、15.8%。
  • 自开始搜索相合无关供者或替代供者起2年内,极不可能组与极可能组生存无差异:单因素HR 1.00(95%CI 0.82-1.21,P=0.98),多因素HR 1.07(95%CI 0.86-1.33,P=0.56)。
  • 移植患者(n=1179)中相合无关供者使用率:极可能组94%、较少可能组38%、极不可能组9%。
  • 多因素分析显示三组移植后复发、治疗相关死亡、无病生存及急性和慢性移植物抗宿主病均无差异。

关键数值与推荐

  • 供者搜索预后评分:极可能找到相合无关供者为>90%,极不可能为<10%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The likelihood of finding a human leukocyte antigen (HLA)-matched unrelated donor (MUD) for hematopoietic cell transplantation can be predicted using a donor search prognosis score. Patients without a MUD may use alternative donors (haploidentical related, mismatched unrelated, or umbilical cord blood). METHODS: This multicenter biological assignment trial was conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1702). Eligibility criteria were broad to mirror clinical practice. The primary end point was 2-year survival from evaluability and compared between those Very Likely (>90%) and Very Unlikely (<10%) to find a MUD. All other patients, Less Likely to find a MUD, were enrolled in an observational arm. Transplant outcomes were compared for all three groups. RESULTS: A total of 1,751 evaluable patients at 47 centers were Very Likely (54.7%), Less Likely (29.5%), and Very Unlikely (15.8%) to identify a MUD. Survival did not differ in univariate (hazard ratio [HR], 1.00 [95% CI, 0.82 to 1.21]; P = .98) or multivariate (HR, 1.07 [95% CI, 0.86 to 1.33]; P = .56) analyses between the Very Unlikely and Very Likely groups, measured through 2 years from the beginning of a search for a MUD or alternative donor. Of the transplanted patients (n = 1,179), MUD was used for 94% of the Very Likely, 38% of Less Likely, and 9% of Very Unlikely patients. Multivariate analyses showed no differences in relapse, treatment-related mortality, disease-free survival, and acute and chronic graft-versus-host diseases for the three search prognosis groups after transplantation. CONCLUSION: Using a donor search prognosis strategy to prioritize an alternative donor for patients Very Unlikely to find a MUD resulted in survival and transplant outcomes that were not statistically different compared with those Very Likely to find a MUD.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lee SJ, Logan B, Horowitz MM, et al. Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation. J Clin Oncol. 2025. PMID: 40966481. doi:10.1200/JCO-25-00206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。